



EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES  
**COMMONWEALTH OF MASSACHUSETTS**  
OFFICE OF MEDICAID  
ONE ASHBURTON PLACE, BOSTON, MA 02108



**MAURA T. HEALEY**  
GOVERNOR

**KIAME MAHANIAH, MD, MBA**  
SECRETARY

**KIMBERLEY DRISCOLL**  
LIEUTENANT GOVERNOR

**MIKE LEVINE**  
UNDERSECRETARY  
FOR MASSHEALTH

November 3, 2025

The Honorable Michael J. Rodrigues  
Chair, Senate Committee on Ways and Means  
State House, Room 212  
Boston, MA 02133

The Honorable Aaron Michlewitz  
Chair, House Committee on Ways and Means  
State House, Room 243  
Boston, MA 02133

The Honorable Cindy Friedman  
Senate Chair, Joint Committee on  
Health Care Financing  
State House, Room 313  
Boston, MA 02133

The Honorable John Lawn  
House Chair, Joint Committee on  
Health Care Financing  
State House, Room 236  
Boston, MA 02133

Dear Chairs Rodrigues, Michlewitz, Friedman, and Lawn,

Enclosed is a 340B/High-Cost Drugs Impact Report, which is required by M.G.L. c. 118E, section 13L. At least 180 days before any restriction or limitation is implemented on an eligible hospital's access to the discounted purchase of prescription drugs to the full extent permitted under section 340B of the federal Public Health Service Act, as codified under 42 U.S.C. § 256b, the Secretary of Health and Human Services is required to submit a report to the Joint Committee on Health Care Financing and the Senate and House Committees on Ways and Means detailing:

- (A) the proposed restriction or limitation;
- (B) the anticipated aggregate savings to the Commonwealth;
- (C) the estimated fiscal impact of the restriction or limitation on each affected hospital; and
- (D) the manner in which the Secretary plans to mitigate the fiscal impact, which may include measures to maintain savings already achieved by providers under said 42 U.S.C. § 256b.

The MassHealth program intends to limit payment for three additional drugs when purchased through the 340B Drug Pricing Program to allow the Commonwealth to benefit from value-based contracts entered into by MassHealth. MassHealth will continue to pay for these three drugs for MassHealth members when purchased outside of the 340B Drug Pricing Program. As

a result, this policy will not impact MassHealth member access to these drugs, or the ability of hospitals to receive payment for these drugs when purchased through the 340B Drug Pricing Program and provided to non-MassHealth patients. This report details the proposed limitation and its anticipated fiscal impact and mitigation.

I hope you find this document useful and informative. Please feel free to contact Sarah Nordberg, Deputy Legislative Director, at [Sarah.Nordberg@mass.gov](mailto:Sarah.Nordberg@mass.gov) if you have any questions about the report.

Sincerely,

A handwritten signature in black ink that reads "Mike Levine". The signature is written in a cursive, flowing style.

Mike Levine  
Undersecretary for MassHealth

cc: Kiame Mahaniah, MD, MBA  
Secretary of the Executive Office of Health and Human Services